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50.56Gy). Median prescribed dose to the supraclavicular area was 42.56. 13 patients were treated with Step and shot and 3, with
VMAT.
Conclusions. Longer follow up will provide data on late toxicity and tumour recurrence in our serie; and likewise, further clinical
study remains important to thoroughly deﬁne the appropriate clinical setting and patient selection criteria for IMRT in breast
cancer.
http://dx.doi.org/10.1016/j.rpor.2013.03.098
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Introduction. The goal of radiation therapy is to decrease toxicity and achieve higher tumor control by increasing the dose and
lowering its margins. Thanks to the new technologies and locking systems we are getting closer to this goal.
Objective. To demonstrate the dose difference received by the organs at risk near the volume in a patient with breast tumor
depending on whether it is treated with the Inclined Plane Immobilizer or Thorax Immobilizer.
Methodology. We conducted a series of CT scan simulations in patients with the Inclined Plane Immobilizer and the Thorax
Immobilizer in order to demonstrate the existing differences in treatment planning. The doctor painted the volumes on both CT
scans and the physics service made the relevant calculations on both treatment plannings in order to measure the differences.
Conclusions. We have observed signiﬁcant differences in terms of the amount of dose reaching the organs at risk near the volume
depending on the immobilization system used.
http://dx.doi.org/10.1016/j.rpor.2013.03.099
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Introduction. IMRT with simultaneous or sequential integrated boost (SIB) is feasible in the treatment of bilateral breast cancer.
This technique can spare organs at risk and is able to give a homogeneous dose distribution in breast volume and surgical bed
(Boost).
Method. Between 2009 and 2012, 6 patients with bilateral breast cancer, 3 received IMRT+SIB, 1 IMRT sequential boost with
electron beam and 2 were treated with three-dimensional radiotherapy. The prescribed dose in integrated boost was 62.5Gy,
breast and supraclavicular fossa (SCF) 50Gy in 25 sessions and 30 sessions in sequential boost. The studied homogeneity index
(HI) was deﬁned as: (D5%−D95%)/breast mean dose. Also was calculated conformity index (CI): V95%/VPTV (both volumes in
cm3, total breast and boost volumes).
Results. 4 patients: TNM variable: TIS T3 N0–N2, no predominant tumor location. Three patients were treated by conserving
surgery+ sentinel lymph node biopsy or lymphadenectomy and one suffered modiﬁcated radical mastectomy. All patients
received adjuvant chemotherapy and hormone treatment. Dosimetric data (range): chest wall volume: 185–215 cm3, breast V:
117–2168 cm3, Boost V: 60–430cm3, SCF V: 234-579 cm3. D107: 0–6.95Gy, Mean Dose 50:53Gy (50.3–56.8Gy), Mean Dose 60: 60.1Gy,
Mean Dose 62.5: 62.7Gy (62.5–63.13Gy). V95: 92.2–97.1%, D5: 52.67–64.4Gy, D95: 48–59.4Gy. CI = 0.08–0.15, HI: 0.75–0.95. Organs
at risk: left lung volume: 890–1110 cm3, left V20=23.9% (17–28.3), left lung mean dose: 15.52Gy (11.2–18.6), Right lung volume:
1162–1296 cm3, right V20 17.75 (17.9–26.9). 11.2–18.6Gy, right lung mean dose: 15.52Gy (11.9–18.6). Heart volume: 334–590 cm3,
V25: 0.7%, heart mean dose: 9.3Gy (4.2–18.7). Left coronary artery (LCA) volume: 2.7–4.9 cm3, LCA mean dose: 7.9Gy (5.3–15.7),
mean LCA maximal dose: 10.31Gy (6.9–17.9).
Conclusion. IMRT in bilateral breast cancer is preferred for individual medical situations. The calculate of homogeneity and
conformity index is very important in treatment quality and it must be evaluated for each patient.
http://dx.doi.org/10.1016/j.rpor.2013.03.100
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Objective. The objective is to compare two techniques for the treatment planning of an internal mammary chain and left breast
mastectomy and axillary and supraclavicular lymph nodes irradiation with two techniques: 3DRT alone (1), versus a combination
of IMRT for mastectomy and internal mammary chain and 3DRT for lymph nodes (2).
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Methods. The target dose is 50Gy in 25 fractions for the PTVs. Only one patient was evaluated. We use a linear accelerator Siemens
Artiste, with 160 leaves MLC of 5mm width at isocenter. Patient orientation is supine and head towards gantry. The most suitable
ﬁxation is tilted plane anchored to treatment table and soft wedge under knees. XiO TPS and step & shoot segmentation were
used. For both techniques we set a single shared isocenter, so we use half ﬁelds. For (1) we arrange the following ﬁelds: 6MV
anterior and 15MV posterior with 15MV auxiliary ﬁelds for axillary PTV; for the mammary chain one 6MV anterior–posterior
ﬁeld and 3 oblique auxiliary ﬁelds of 6MV and 15MV. For the breast, we use 6MV tangential ﬁelds and 15MV auxiliary ﬁelds. For
(2) we arrange the same as in (1) for axillary PTV; for the breast, 6MV tangential ﬁelds and 15MV auxiliary ﬁelds and 3 intensity
modulated ﬁelds with tangential internal, anterior and oblique incidence angle.
Results. Improvements shifted from 37% to 34% in lung for V20, from 27% to 22% in heart for V33, and from 49Gy to 49.6Gy in
PTV for mean dose. Nevertheless, mammary chain coverage (95% isodose volume) shifted from 94% to 91%.
Discussion. With technique 2, the left lung gets less dose than with technique 1. Although (1) got better coverage, (2) achieved
better homogeneity and without hot points. It is feasible to deliver breast treatments combining IMRT and 3DRT, achieving less
dose in the lung.
http://dx.doi.org/10.1016/j.rpor.2013.03.101
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Introduction. Over the last 10 years, intra-operative radiotherapy (IORT) has been used extensively in clinical trials but has yet
to make a signiﬁcant clinical impact on current breast cancer management strategies. There are currently two devices that
ﬁt the category of electronic brachytherapy. The Axxent® Electronic Brachytherapy System (Xoft Inc., Fremont, CA) using low-
energy radiation at a high dose rate and the Zeiss Intrabeam® (Carl Zeiss Surgical Gmbh, Oberkochen, Germany) a mobile photon
radiation system that procures a miniature electron beam driven X-ray source.
Purpose. We present our experience at Hospital de La Mancha Centro with IORT in selected patients using the Zeiss INTRABEAM®
system.
Materials and methods. We have analyzed 15 patients across from May to December 2011. Depending on clinical characteristics,
two groups of patients were treated either to accelerated partial breast irradiation (APBI) or a BOOST followed by whole breast
radiation therapy (WBRT). Main inclusion criteria for APBI patients were: (a) signature of informed consent; (b) indication for
breast conservative surgery; (c) age≥60 years; (d) histology: CDI or other favourable histology; (e) unicentric and unifocal tumor;
(f) negative margins (≥2mm); (g) sentinel lymph node negative; (h) ER negative; (i) WBRT contraindicated. Patients unsuitable for
APBI were offered IORT as boost. Doses administered for APBI and BOOST were 20Gy and 10–20Gy, respectively
Results. 9 out 15 patientswere derived to APBI and 6 to Boost plusWBRT; however, surgery ﬁnally demonstrated that somepatients
did not meet criteria and ﬁnally we did 4 APBI, 10 boost +WBRT and 1 EBRT. In all cases analyzed, the most frequent toxicity
associated to the treatment was: seroma, hyperpigmentation, edema and ﬁbrosis. After a minimum follow-up of 12 months
(median 24) no local relapses were observed.
Conclusions. Although the information was based from an extremely limited source of patients we can conclude that IORT using
the Intrabeam System is a suitable treatment for early stage breast cancer in appropriately selected patients according to ASTRO
or ASTRO guidelines.
http://dx.doi.org/10.1016/j.rpor.2013.03.102
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Purpose. To evaluate feasibility, tolerability and cosmetic outcome of intraoperative radiation therapy (IORT) as an exclusive
post-surgery treatment or anticipated boost of early stage breast cancer (BC).
Patients and methods. From February 2009 to December 2012, 33 eligible patients were treated with breast-conserving surgery
followed by IORT to the reconstructed tumor bed delivered using a linear accelerator. The doses were 21 or 10Gy depends on
results of sentinel lymph nodes biopsy. The clinical stages of patients were: 29 (87.9%) Stage I (cT1cN0) and 4 (12.1%) Stage IIA
